Shares of Neurogene Inc. (NASDAQ:NGNE – Get Free Report) have received an average recommendation of “Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $51.00.
Several equities research analysts have recently issued reports on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Neurogene in a research report on Monday, April 29th. Robert W. Baird started coverage on Neurogene in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $54.00 price target on the stock. HC Wainwright reduced their price objective on Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Monday. Baird R W raised Neurogene to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, SVB Leerink assumed coverage on Neurogene in a research note on Monday, April 29th. They issued an “outperform” rating and a $46.00 target price on the stock.
Read Our Latest Report on Neurogene
Institutional Inflows and Outflows
Neurogene Price Performance
NASDAQ:NGNE opened at $35.62 on Friday. Neurogene has a 1 year low of $12.49 and a 1 year high of $53.00. The stock has a 50-day moving average price of $38.11 and a two-hundred day moving average price of $36.38.
Neurogene (NASDAQ:NGNE – Get Free Report) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The company had revenue of $0.93 million during the quarter. Research analysts expect that Neurogene will post -4.15 earnings per share for the current fiscal year.
Neurogene Company Profile
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories
- Five stocks we like better than Neurogene
- Learn Technical Analysis Skills to Master the Stock Market
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Best Stocks Under $5.00
- Jeff Brown’s Exegesis AI Stock Picks
- What is the Australian Securities Exchange (ASX)
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.